← The Wire
RGNXNasdaq
REGENXBIO Inc.
Biological Products, (No Diagnostic Substances) · CIK 1590877
Develops gene therapy treatments using its NAV Technology Platform for genetic defects and therapeutic protein production
⚡ Elevated coverage
$344M
Market cap
$11.83
Last close
+12.9%
1D
+30.4%
5D
2.5M
Volume
Price · last 39 sessions+26.0%
May 4L $5.65 · H $11.83Jun 29
215
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
8-KCompany UpdateJun 29, 20268-KShareholder Vote · Company UpdateJun 3, 202610-Q10-QMay 14, 20268-KResults of Operations · Reg FD DisclosureMay 14, 2026DEFA14ADEFA14AApr 14, 2026DEF 14ADEF 14AApr 14, 20268-KMaterial AgreementMar 20, 202610-K10-KMar 5, 20268-KResults of OperationsMar 5, 2026424B5424B5Feb 12, 20268-KReg FD Disclosure · Company UpdateFeb 10, 20268-KCompany UpdateJan 28, 20268-KResults of OperationsNov 6, 202510-Q10-QNov 6, 20258-KCompany UpdateAug 18, 202510-Q10-QAug 7, 20258-KMaterial Agreement · Results of OperationsAug 7, 20258-KShareholder VoteJun 3, 20258-KMaterial Agreement · New Debt / ObligationMay 19, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 8, 2025DEF 14ADEF 14AApr 8, 202510-K10-KMar 13, 20258-KResults of OperationsMar 13, 20258-KReg FD Disclosure · Company UpdateMar 4, 20258-KMaterial Agreement · Reg FD DisclosureJan 14, 2025424B5424B5Dec 9, 20248-KCompany UpdateDec 9, 202410-Q10-QNov 6, 20248-KResults of OperationsNov 6, 20248-KExecutive Change · Reg FD DisclosureSep 17, 20248-KExecutive ChangeAug 6, 202410-Q10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KExecutive Change · Reg FD DisclosureJun 13, 20248-KShareholder VoteJun 3, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 4, 2024DEF 14ADEF 14AApr 4, 20248-KCompany UpdateMar 11, 2024424B5424B5Mar 8, 2024424B5424B5Mar 6, 202410-K10-KFeb 27, 20248-KResults of OperationsFeb 27, 2024SC 13GSC 13GNov 17, 202310-Q10-QNov 8, 20238-KResults of OperationsNov 8, 2023424B5424B5Sep 1, 20238-KCompany UpdateSep 1, 202310-Q10-QAug 2, 20238-KResults of OperationsAug 2, 20238-KShareholder VoteJun 5, 202310-Q10-QMay 3, 20238-KResults of OperationsMay 3, 2023SC 13GSC 13GApr 7, 2023DEFA14ADEFA14AApr 6, 2023DEF 14ADEF 14AApr 6, 202310-K10-KFeb 28, 20238-KResults of OperationsFeb 28, 20238-KExecutive ChangeJan 10, 202310-Q10-QNov 3, 20228-KResults of OperationsNov 3, 202210-Q10-QAug 3, 20228-KResults of OperationsAug 3, 20228-KExecutive Change · Shareholder VoteJun 7, 202210-Q10-QMay 4, 20228-KResults of OperationsMay 4, 2022DEFA14ADEFA14AApr 7, 2022DEF 14ADEF 14AApr 7, 20228-KMaterial AgreementMar 25, 20228-KExecutive ChangeMar 18, 202210-K10-KMar 1, 20228-KResults of OperationsMar 1, 20228-KReg FD Disclosure · Company UpdateFeb 14, 20228-KReg FD Disclosure · Company UpdateFeb 9, 20228-KMaterial AgreementNov 15, 20218-KReg FD Disclosure · Company UpdateNov 12, 20218-KReg FD Disclosure · Company UpdateNov 9, 2021
Insider Activity
In the 90 days to Mar 10, 2026: 1 sold $53K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 | Pakola SteveChief Medical Officer | Sell | 5,124 | $10.35 | $53K |
| Oct 9, 2025 | Simpson CurranChief Executive Officer | Sell | 20,811 | $12.62 | $263K |
| Sep 29, 2025 | Simpson CurranChief Executive Officer | Sell | 7,624 | $10.03 | $76K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance